Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Lars Fruergaard Jørgensen, the chief executive of once-highflying Danish drug manufacturer Novo Nordisk, is stepping down ...

Bagsværd, Denmark, 9 May 2025 - This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons ...

[COPENHAGEN] Obesity drugmaker Novo Nordisk said on Wednesday (May 7) it would drop gender representation requirements for its US business following executive orders by President Donald Trump to stop ...

Novo Nordisk beat earnings estimates but slightly missed top-line revenue expectations. However, the results throughout its business were quite strong, and management gave an upbeat outlook for ...

On Wednesday, BofA Securities revised its price target for Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) shares, lowering it to DKK850 from the previous DKK910. Despite the reduction, the firm ...